The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Open accessAbstract
Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor gene product p53. Ectopic miR-34a induces a G(1) cell cycle arrest, senescence and apoptosis. Here we report that miR-34a expression is silenced in several types of cancer due to aberrant CpG methylation of its promoter. 19 out of 24 (79.1%) primary prostate carcinomas displayed CpG methylation of the miR-34a promoter and concomitant loss of miR-34a expression. CpG methylation of the miR-34a promoter was also detected in breast (6/24; 25%), lung (7/24; 29.1%), colon (3/23; 13%), kidney (3/14; 21.4%), bladder (2/6; 33.3%) and pancreatic (3/19; 15.7%) carcinoma cell lines, as well as in melanoma cell lines (19/44; 43.2%) and primary melanoma (20/32 samples; 62.5%). Silencing of miR-34a was dominant over its transactivation by p53 after DNA damage. Re-expression of miR-34a in prostate and pancreas carcinoma cell lines induced senescence and cell cycle arrest at least in part by targeting CDK6. These results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
The power and the promise of DNA methylation markers
Laird, P. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1045 · Cited by 1,562
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,123
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4436 · Cited by 923
Self-citationTazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
Welch, C., Chen, Y., & Stallings, R. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210293 · Cited by 805
Exploration of Tumor-Suppressive MicroRNAs Silenced by DNA Hypermethylation in Oral Cancer
Kozaki, K.-I., Imoto, I., Mogi, S., Omura, K., & Inazawa, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5194 · Cited by 613
Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., & Tokino, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0325 · Cited by 600
Argonaute proteins: mediators of RNA silencing
Peters, L., & Meister, G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.001 · Cited by 598
Downregulation of CCND1 and CDK6 by miR‐34a induces cell cycle arrest
Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., Sun, Z., & Zheng, X. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.03.057 · Cited by 514
Hermeking, H. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.028 · Cited by 494
Self-citationHistone modifications and silencing prior to DNA methylation of a tumor suppressor gene
Bachman, K. E., Park, B. H., Rhee, I., Rajagopalan, H., Herman, J. G., Baylin, S. B., Kinzler, K. W., & Vogelstein, B. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00234-9 · Cited by 418
A functional study of miR-124 in the developing neural tube
Cao, X., Pfaff, S. L., & Gage, F. H. (2007) · Genes & Development · doi:10.1101/gad.1519207 · Cited by 336
The Guardian's Little Helper: MicroRNAs in the p53 Tumor Suppressor Network
He, X., He, L., & Hannon, G. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2672 · Cited by 317
A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene
Cole, K. A., Attiyeh, E. F., Mosse, Y. P., Laquaglia, M. J., Diskin, S. J., Brodeur, G. M., & Maris, J. M. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2102 · Cited by 316
The MYCN oncogene is a direct target of miR-34a
Wei, J. S., Song, Y. K., Durinck, S., Chen, Q.-R., Cheuk, A. T. C., Tsang, P., Zhang, Q., Thiele, C. J., Slack, A., Shohet, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.154 · Cited by 296
Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer
Lodygin, D., Epanchintsev, A., Menssen, A., Diebold, J., & Hermeking, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4407 · Cited by 286
Self-citationKarpf, A. R., Moore, B. C., Ririe, T. O., & Jones, D. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09243-5 · Cited by 176
MicroRNAs in malignant progression
Ma, L., & Weinberg, R. A. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5547 · Cited by 136
Basic Fibroblast Growth Factor and Ultraviolet B Transform Melanocytes in Human Skin
Berking, C., Takemoto, R., Satyamoorthy, K., Elenitsas, R., & Herlyn, M. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64041-2 · Cited by 83
Self-citationDigital Karyotyping Reveals Frequent Inactivation of the dystrophin/DMD Gene in Malignant Melanoma
Körner, H., Epanchintsev, A., Berking, C., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.2.3733 · Cited by 26
Self-citationInducible microRNA expression by an all-in-one episomal vector system
Epanchintsev, A., Jung, P., Menssen, A., & Hermeking, H. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl624 · Cited by 24
Self-citation
Cited by
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236
Self-citationMicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
Metadata
- Authors
- Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2008-08-15
- Volume
- 7
- Issue
- 16
- Pages
- 2591-2600
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2156843318
- Cited by
- 784
- References
- 29
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.